Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-07 pm EST			5-day change	1st Jan Change
1.8 ^USD	-4.76%		+20.00%	-73.80%

Dec. 04	Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan	CI
Nov. 13	Neuronetics, Inc. Elevates Depression Treatment with Cutting-Edge Technology Advancements	CI

Declaration of Voting Results by Neuronetics Inc

May 30, 2023 at 04:04 pm EDT

On May 30, 2023, Neuronetics Inc announced that it held its 2023 annual meeting of shareholders on May 25, 2023 and declared the voting results. As there has been no further engagement between Cannell Capital LLC and Neuronetics Inc, hence the campaign is considered to have been withdrawn.

Latest news about Neuronetics, Inc.

Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan	Dec. 04	CI
Neuronetics, Inc. Elevates Depression Treatment with Cutting-Edge Technology Advancements	Nov. 13	CI
Transcript : Neuronetics, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07	CI
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $17.9M	Nov. 07	MT
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	Nov. 07	CI
Neuronetics, Inc. Enters into Fifth Amendment to Loan and Security Agreement with SLR Investment Corp	Oct. 03	CI
Neuronetics Draws Down Remaining $22.5 Million From SLR Capital Credit Facility	Oct. 03	MT
Neuronetics, Inc. Draws Down Remaining $22.5 Million Available Under Credit Facility	Oct. 03	CI
Neuronetics, Inc.(NasdaqGM:STIM) dropped from S&P Global BMI Index	Sep. 18	CI
Neuronetics, Inc. Announces the Launch of the NeuroStar Voices Portal	Sep. 12	CI
Neuronetics, Inc. Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar Platform	Aug. 14	CI
Transcript : Neuronetics, Inc., Q2 2023 Earnings Call, Aug 08, 2023	Aug. 08	CI
Earnings Flash (STIM) NEURONETICS Reports Q2 Revenue $17.6M, vs. Street Est of $17.5M	Aug. 08	MT
Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	Aug. 08	CI
Neuronetics, Inc. Provides Revenue Guidance for the Third Quarter of 2023	Aug. 08	CI
Neuronetics, Inc. Revises Revenue Guidance for the Year Full Year 2023	Aug. 08	CI
North American Morning Briefing : Sentiment Hit by -2-	Aug. 08	DJ
Neuronetics Says Aetna to Offer Expanded Coverage for NeuroStar Therapy	Jul. 19	MT
Neuronetics, Inc Announces Expanded TMS Therapy Access Through Aetna® Health Plans	Jul. 19	CI
Neuronetics Gets South Korea's Approval for Expanded Features in NeuroStar Therapy	Jul. 17	MT
Neuronetics, Inc.(NasdaqGM:STIM) added to Russell 3000E Growth Index	Jun. 23	CI
Neuronetics, Inc.(NasdaqGM:STIM) added to Russell Microcap Growth Index	Jun. 23	CI
Neuronetics Receives 510(K) Clearance for Ocd Mt Cap for Neurostar Advanced Therapy	Jun. 12	CI
Declaration of Voting Results by Neuronetics Inc	May. 30	CI

Chart Neuronetics, Inc.

Duration

Period

More charts

Company Profile

Neuronetics, Inc. is a commercial stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-03-04 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Neuronetics, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.8USD

Average target price

6USD

Spread / Average Target

+233.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NEURONETICS, INC.	-73.80%	55 M $
THERMO FISHER SCIENTIFIC	-10.28%	191 B $
DANAHER CORPORATION	-17.52%	163 B $
INTUITIVE SURGICAL, INC.	+17.41%	109 B $
BOSTON SCIENTIFIC CORPORATION	+18.93%	80 310 M $
SIEMENS HEALTHINEERS AG	+11.71%	63 346 M $
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-10.43%	47 620 M $
EDWARDS LIFESCIENCES CORPORATION	-8.51%	42 146 M $
AGILENT TECHNOLOGIES, INC.	-14.01%	37 658 M $
GE HEALTHCARE TECHNOLOGIES INC.	+15.43%	30 979 M $

Other Advanced Medical Equipment & Technology